Aurinia Pharmaceuticals Inc.
AUPHDrugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Aurinia Reports Financial Results
Filed: 2026-05-07 AccNo: 0001600620-26-000048 Size: 314 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source0.05% Voclosporin Ophthalmic Solution (VOS)
Dry Eye Syndrome
Voclosporin
Lupus Nephritis
Ciclosporin
Psoriasis
Voclosporin High Dose
Lupus Nephritis
tacrolimus
Kidney Diseases
Voclosporin Ophthalmic Solution
Dry Eye
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
0.05% Voclosporin Ophthalmic Solution (VOS) | Phase 3 | Dry Eye Syndrome | - | - |
Voclosporin | Phase 3 | Lupus Nephritis | - | - |
Ciclosporin | Phase 3 | Psoriasis | - | - |
Voclosporin High Dose | Phase 2 | Lupus Nephritis | - | - |
tacrolimus | Phase 2 | Kidney Diseases | - | - |
Voclosporin Ophthalmic Solution | Phase 2 | Dry Eye | - | - |
Lupus Nephritis
3 drugs in this indication
Psoriasis
2 drugs in this indication
Kidney Diseases
1 drug in this indication
Dry Eye Syndrome
1 drug in this indication
Dry Eye
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)